Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNLOCK ASP3082
2025-522533-54-00Phase 2Authorised
- Sponsor
- Gustave Roussy
- Start
- Jan 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of setidegrasib in non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma (PDAC), sponsored by Gustave Roussy. Primary endpoint: Best overall response (BOR). Planned start Jan 2026; status: authorised.
02
Drugs
setidegrasib
03
Conditions
non-small cell lung cancer (NSCLC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2025-522533-54-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522533-54-00.